Premarin
NDC Package 53808-0770-1
Package Information
Premarin is a medication a female hormone. Marketed by State Of Florida Doh Central Pharmacy, this product is identified by NDC 53808-0770 and is authorized under FDA application NDA004782.
Identification & Billing
- RxCUI: 150840 - PREMARIN 0.625 MG Oral Tablet
- RxCUI: 150840 - estrogens, conjugated (USP) 0.625 MG Oral Tablet [Premarin]
- RxCUI: 150840 - Premarin 0.625 MG Oral Tablet
- RxCUI: 310197 - estrogens, conjugated 0.625 MG Oral Tablet
- RxCUI: 310197 - estrogens, conjugated (USP) 0.625 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 53808 - State Of Florida Doh Central Pharmacy
- 53808-0770 - Premarin
- 53808-0770-1 - 30 TABLET, FILM COATED in 1 BLISTER PACK
- 53808-0770 - Premarin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 53808-0770-1 identifies a specific commercial package of 30 tablet, film coated in 1 blister pack of Premarin, labeled by State Of Florida Doh Central Pharmacy. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by State Of Florida Doh Central Pharmacy on July 01, 2009. The current certification is valid through December 31, 2017.
What are the primary indications for this medication?
This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).
How is this State Of Florida Doh Central Pharmacy product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 53808077001. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.